Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801

• Enrique Espinosa ^[1] ; Miguel-Ángel Berciano-Guerrero ^[19] ; Eva Muñoz-Couselo ^[20] ; Teresa Puértolas ^[2] ; José Luis Manzano ^[21] ; Ainara Soria ^[3] ; Pablo Ayala de Miguel ^[22] ; Guillermo Crespo ^[4] ; Lourdes Gutiérrez Sanz ^[5] ; Pablo Cerezuela-Fuentes ^[6] ; Carlos Aguado de la Rosa ^[7] ; Margarita Majem ^[8] ; Almudena García Castaño ^[9] ; Alfonso Berrocal ^[10] ; Francisco Ramón García Arroyo ^[11] ; María Rodríguez de la Borbolla ^[12] ; Lorena Bellido ^[13] ; Javier Medina Martínez ^[23] ; Luis Antonio Fernández ^[24] ; Alfonso Martín Carnicero ^[25] ; Rafael López Castro ^[14] ; Aida Bujosa Rodríguez ^[15] ; Mª José Lecumberri ^[16] ; José Carlos Villa Guzmán ^[17] ; Iván Márquez-Rodas ^[18]
  1. [1] Universidad Autónoma de Madrid

     Universidad Autónoma de Madrid

     Madrid, España

     
  2. [2] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  3. [3] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  4. [4] Complejo Asistencial Universitario de Burgos

     Complejo Asistencial Universitario de Burgos

     Burgos, España

     
  5. [5] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  6. [6] Hospital Virgen de la Arrixaca

     Hospital Virgen de la Arrixaca

     Murcia, España

     
  7. [7] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  8. [8] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  9. [9] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  10. [10] Hospital General Universitario de Valencia

      Hospital General Universitario de Valencia

      Valencia, España

      
  11. [11] Complexo Hospitalario Universitario de Pontevedra

      Complexo Hospitalario Universitario de Pontevedra

      Pontevedra, España

      
  12. [12] Hospital Universitario de Valme

      Hospital Universitario de Valme

      Sevilla, España

      
  13. [13] Instituto de Investigación Biomédica de Salamanca

      Instituto de Investigación Biomédica de Salamanca

      Salamanca, España

      
  14. [14] Hospital Universitario de Valladolid

      Hospital Universitario de Valladolid

      Valladolid, España

      
  15. [15] Hospital Son Llàtzer

      Hospital Son Llàtzer

      Palma de Mallorca, España

      
  16. [16] Hospital Universitario de Navarra

      Hospital Universitario de Navarra

      Pamplona, España

      
  17. [17] Hospital General de Ciudad Real

      Hospital General de Ciudad Real

      Ciudad Real, España

      
  18. [18] Hospital General Universitario Gregorio Marañón

      Hospital General Universitario Gregorio Marañón

      Madrid, España

      
  19. [19] Medical Oncology Department, Hospital Regional Universitario (HRU), Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Málaga, Spain
  20. [20] Medical Oncology Department, Hospital Universitari Vall d’Hebron y Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
  21. [21] Medical Oncology Department, Instituto Catalán de Oncología, ICO-Badalona, H. Germans Trias i Pujol, Badalona, Spain
  22. [22] Medical Oncology Department, Hospital Universitario San Pedro de Alcántara, Cáceres, Spain
  23. [23] Medical Oncology Department, Hospital Universitario de Toledo, Toledo, Spain
  24. [24] Medical Oncology Department, Hospital Universitari Parc Taulí de Sabadell, Sabadell, Spain
  25. [25] Medical Oncology Department, Hospital San Pedro de La Rioja, Logroño, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 28, Nº. 5, 2026, págs. 1807-1814
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose:

    Anti-PD-1-based immunotherapy and targeted therapies (TT) are the current standard of care for patients with advanced melanoma. However, some patients die in less than a year from diagnosis and others become long-survivors. An accurate description of systemic treatments and patients’ characteristics of long-term survivors are needed to guide treatment decisions in clinical practice.

    Methods:

    GEM-1801 is a multi-cohort prospective study from the Spanish Multidisciplinary Melanoma Group that includes patients with resectable stage III or unresectable stage III/IV melanoma. Patients surviving at least 5 years and patients surviving less than 1 year since diagnosis were selected. Baseline characteristics and first and second-line systemic treatments are described and compared between groups.

    Results:

    From Aug 2018 to Dec 2023, 60 patients with long-term survival and 216 patients with short-term survival were included. Long-term survivors received immunotherapy (65%), including anti-PD-1 in 86% and combination of an anti-PD-1 and anti-CTLA-4 in 14%; and TT (35%). The Objective Response Rate (ORR) was 76% for anti-PD-1, 80% for combination immunotherapy and 83% for TT. Short-term survivors received immunotherapy (58%), including anti-PD-1 (70%), anti-CTLA-4 (1%), and anti-PD-1 plus anti-CTLA-4 (29%); TT (36%); and chemotherapy (2%). ORR was 7% for anti-PD-1, 0% for anti-CTLA-4, 14% for combination immunotherapy, 53% for TT and 0% for chemotherapy.

    Conclusions:

    Response to first or second-line systemic treatment may be a surrogate for long-term survival patients with advanced melanoma.